Skip to main content
SpringerLink
Log in

Neue immunmodulierende Strategien in der Dermatologie

  • Conference paper
Fortschritte der praktischen Dermatologie und Venerologie

Part of the book series: Fortschritte der praktischen Dermatologie und Venerologie ((DERMATOLOGIE,volume 17))

  • 147 Accesses

Zusammenfassung

In den vergangenen Jahren konnten enorme Fortschritte im Verständnis der Pathogenese von entzündlichen und immunologisch bedingten Dermatosen erzielt werden. Diese Erkenntnisse sowie die faszinierenden Neuerungen auf den verschiedenen Gebieten der Biotechnologie haben die Entstehung und den Einsatz völlig neuer Immunmodulatoren ermöglicht. Dabei kommen einerseits unspezifisch wirkend Immuntherapeutika zum Einsatz und andererseits hochspezifische Agonisten oder Antagonisten. Außerdem befinden sich völlig neue Strategien wie die Verwendung von in vitro modifizierten Anti-gen-präsentierenden Zellen, Antisense-Oligonukleotiden sowie gentherapeutische Ansätze in Erprobung (Tabelle 1). Im Folgenden soll ein Überblick über Auswahl von einigen für die Dermatologie relevanten Immuntherapeutika gegeben werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., Weiner R.S., Birkhofer M.J., Warner G.L., Berry K.K., Linsley P.S., Krueger J.G., Ochs H.D., Kelley S.L., Kang S. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243–1252

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Antman K., Chang Y. (2000) Kaposi’s sarcoma. N Engl J Med 342: 1027–1038

    Article  CAS  PubMed  Google Scholar 

  3. Arany I., Tyring S.K., Stanley M.A., Tomai M.A., Miller R.L., Smith M.H., McDermott D.J., Slade H.B. (1999) Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5 %. Antiviral Res 43: 55–63

    Article  CAS  PubMed  Google Scholar 

  4. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., Volk H.D., Döcke W-D. (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101: 783–794

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Becker J.C., Lode H.N., Straten P.T., Reisfeld R.A. (1999) Targeted interleukin-2 therapy for melanoma by immunocytokines. Dermatol Ther 10: 53–61

    Google Scholar 

  6. Beissert S., Luger T.A. (1999) Future developments of antipsoriatic therapy. Dermatol Ther 11: 104–117

    Google Scholar 

  7. Belardelli F., Gresser I. (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17: 369–372

    Article  CAS  PubMed  Google Scholar 

  8. Beutner K.R., Geisse J.K., Helman D., Fox T.L., Ginkel A., Owens M.L. (1999) Therapeutic response ofbasal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol 41: 1002–1007

    Article  CAS  PubMed  Google Scholar 

  9. Beutner K.R., Spruance S.L., Hougham A.J., Fox T.L., Owens M.L., Douglas J.M. (1998) Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 38: 230–239

    Article  CAS  PubMed  Google Scholar 

  10. Bhattacharya S.K., Ramchandani S., Cervoni N., Szyk M. (1999) A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397: 579–583

    Article  CAS  PubMed  Google Scholar 

  11. Boguniewicz M., Fiedler V.C., Raimer S., Lawrence I.D., Leung D.Y., Hanifin J.M. (1998) A randomized, vehiclecontrolled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 102: 637–644

    Article  CAS  PubMed  Google Scholar 

  12. Böhm M., Beissert S., Schwarz T., Metze D., Luger T. (1997) Bullous pemphigoid treated with mycophenolate mofetil. Lancet 349: 541

    Article  PubMed  Google Scholar 

  13. Breedveld F.C. (2000) Therapeutic monoclonal antibodies. Lancet 355: 735–740

    Article  CAS  PubMed  Google Scholar 

  14. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., Johnson P., Lister A., Feuring-Buske M., Radford J.A, Capdeville R., Diehl V., Reyes F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927–1932

    CAS  PubMed  Google Scholar 

  15. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., Jonas C., Klippenstein D., Dallaire B., Varns C. (1999) Treatment of patients with low-grade Bcell lymphoma with the combination of chimeric antiCD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268–276

    CAS  PubMed  Google Scholar 

  16. De Rie M.A., Meinardi M.M., Bos J.D. (1991) Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 71: 452–454

    CAS  PubMed  Google Scholar 

  17. Demiroglu H.,. Özcebe O.I., Barista I., Dündar S., EIdern B. (2000) Interferon alfa-2b, colchicine, and benzatine penicillin versus colchicine and benzatine penicillin in Behcet’s disease: a randomized trial. Lancet 355: 605–609

    Article  CAS  PubMed  Google Scholar 

  18. Durharn S.R., Walker S.M., Varga E.M., Jacobson M.R., O’Brien F., Noble W., Till S.J., Hamid Q., Nouri-Aria K.T. (1999) Long-term clinieal efficacy of grass-pollen immunotherapy. N Engl J Med 341: 468–475

    Article  Google Scholar 

  19. Dytoc M.T., Sauder D.N. (1998) Cytokine therapy in skin dis orders. Dermatol Ther 5: 34–47

    Google Scholar 

  20. Enk A., Nashan D., Rübben A., Knop J. (2000) High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer 88: 2042–2046

    Article  CAS  PubMed  Google Scholar 

  21. Enk A.H., Knop J. (1997) Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 350: 494

    Article  CAS  PubMed  Google Scholar 

  22. Ezekowitz R.A.B., Mulliken J.B., Folkman J. (1992) Interferon alpha 2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326: 1456–1463

    Article  CAS  PubMed  Google Scholar 

  23. Fekade D., Knox K., Hussein K., Melka A., Lalloo D.G., Coxon R.E., Warrell D.A. (1996) Prevention ofJarisch-Herxheimer reactions by treatment with antibioties against tumor necrosis factor alpha. N Engl J Med 335: 311–315

    Article  CAS  PubMed  Google Scholar 

  24. Fleischer A.B. Jr (1999) Treatment of atopie dermatitis: role oftacrolimus ointment as a topieal noncorticosteroidal therapy. J AHergy Clin Immunol 104: 126–130

    Article  Google Scholar 

  25. Geilen C.C., Orfanos-Boeckel H., Offermann G., Orfanos C.E. (2000) Mycophenolate mofetil: Ein neues Immunsuppressivum in der Dermatologie und seine Einsatzmögchkeiten. Hautarzt 51: 63–69

    Article  CAS  PubMed  Google Scholar 

  26. Gottlieb A., Abdulghani A., Totoritis M., Lizambri R., Shuey S., Romano P., Oh C.J., Chaudhari U., Lebwohl M. (2000) Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis. J luvest Dermatol 114: 840

    Google Scholar 

  27. Gottlieb A., Miller B., Chaudhari U., Oh C.J., Sherr A., Solodkina G., Shapiro W., Hudson C., Lowe N., Bright R., Ling M., Magee A., McCall C., Rist T., Krueger J., Garovoy M. (2000) Clinical and histologie effects of subcutaneously administered anti-CDlla (hU1124) in patients with psoriasis. J Invest Dermatol 114: 840

    Google Scholar 

  28. Gottlieb A.B., Bacha P., Parker K., Strand V. (1998) Use of interleukin-2 fusion protein, DAB389IL-2, for the treatment of psoriasis. Dermatol Ther 5: 48–63

    Google Scholar 

  29. Granlund H., Erkko P., Reitamo S. (1998) Long-term follow-up of eczema patients treated with cyclosporine. Acta Derm Venereol 78: 40–43

    Article  CAS  PubMed  Google Scholar 

  30. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., Schuler W., Schulz M., Werner F.I., Winiski A., Wolff B., Zenke G. (1999) A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141: 264–273

    Article  CAS  PubMed  Google Scholar 

  31. Grosfeld J.L., Du X., Williams D.A. (1999) Interleukin-11: its biology and prospects for clinieal use. JPEN J Parenter Enteral Nutr 23: S67–S69

    Article  CAS  PubMed  Google Scholar 

  32. Gross G., Rogozinski T., Schöfer H., Jablonska S., Roussaki A., Wöhr C., Brzoska J. (1998) Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controHed double-blind study in 120 patients. Dermatology 196: 330–334

    Article  CAS  PubMed  Google Scholar 

  33. Gupta A.K., Sauder D.N. (1998) The use of cyclosporine to treat cutaneous diseases. Dermatol Ther 5: 64–73

    Google Scholar 

  34. Hanifin J.M., Chan S. (1999) Biochemiealand immunologie mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 41: 72–77

    Article  CAS  PubMed  Google Scholar 

  35. Haufs M.G., Beissert S., Grabbe S., Schütte B., Luger T.A. (1998) Psoriasis vulgaris treated successfuHy with mycophenolate mofetil. Br J Dermatol 138: 179–181

    Article  CAS  PubMed  Google Scholar 

  36. Kagy M.K., Amonette R. (2000) The use of imiquimod 5 % cream for the treatment of superficial basal ceH carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 26: 577–578

    Article  CAS  PubMed  Google Scholar 

  37. Kapion R.J., Hochman P.S., Miehler R.E., Kwiatkowski P.A., Edwards N.M., Berger C.L., Xu H., Meier W., WaHner B.P., Chisholm P., Marboe C.C. (1996) Short course single agent therapy with an LFA-3-lgG1 fusion protein prolongs primate cardiac aHograft survival. Transplantation 61: 356–363

    Article  Google Scholar 

  38. Kashani-Sabet M. (1999) Toward the biologie treatment of nonmelanoma skin cancer. J Am Acad Dermatol 41: 1018–1019

    Article  CAS  PubMed  Google Scholar 

  39. Kawashima M., Nakagawa H., Ohtsuki M., Tamaki K., Ishibashi Y. (1996) Tacrolimus concentrations in blood during topieal treatment of atopie dermatitis [letter]. Lancet 348: 1240–1241

    Article  CAS  PubMed  Google Scholar 

  40. Kitchin J.E., Pomeranz M.K., Pak G. (1997) Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 37: 445–449

    Article  CAS  PubMed  Google Scholar 

  41. Lawrence I.D. (1998) Tacrolimus (FK506): experience in dermatology. Dermatol Ther 5: 74–84

    Google Scholar 

  42. Lebwohl M., Ellis C., Gottlieb A., Koo J., Krueger G., Linden K., Shupack J., Weinstein G. (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 39: 464–475

    Article  CAS  PubMed  Google Scholar 

  43. Lotze M.T., Hellerstedt B., Stolinski L., Tüting T., Wilson C., Kinzier D., Vu H., Rubin J.T., Storkus W., Tahara H., Eider E., Whiteside T. (1997) The role ofinterleukin-2, interleukin-12, and dendritie ceHs in cancer therapy. Cancer J Sci Am 3 [SUppl 1]:S109–S114

    PubMed  Google Scholar 

  44. Lotze M.T., Zeh H.J. III, Eider E.M., Cai Q., Pippin B.A., Rosenstein M.M., Whiteside T.L., Herberman R. (1992) Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. J Immunother 12: 212–217

    Article  CAS  PubMed  Google Scholar 

  45. Luger T.A., Beissert S., Schwarz T. (1997) The epidermal cytokine network. In: Bos JD (ed) Skin Immune System (SIS). CRC Press, Boca Raton, pp 271–310

    Google Scholar 

  46. Luger T.A., Leent E.J. van, Graeber M., Hedgecock S., Thurston M., Kandra A., Berth Jones J., Bjerke J., Christophers E., Knop J., Knulst A.C., Morren M., Morris A., Reitamo S., Roed-Petersen J., Schöpf E., Thestrup-Pedersen K., Valk P.G.M. van der, Bos J. (2001) SDZ ASM981: an emerging new standard for the treatment of atopic dermatitis. Br J Dermatol:(im Druck)

    Google Scholar 

  47. Matsue H., Matsue K., Walters M., Okumura K., Yagita H., Takashima A. (1999) Induction of antigen-specific immunosuppression by CD95L cDNA-transfected „killer“ dendritie cells. Nat Med 5: 930–937

    Article  CAS  PubMed  Google Scholar 

  48. Mease P.J., Goffe B.S., Metz J., Stoep A. van der, Finck B., Burge D.J. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385–390

    Article  CAS  PubMed  Google Scholar 

  49. Meingasser J.G., Fahrngruber H., Bavandi A. (2000) SDZ ASM981, in contrast to CyA and FK506, does not suppress the primary immune response in murine allergie contact dermatitis. J luvest Dermatol 114: 832

    Google Scholar 

  50. Meingassner J.G., Grassberger M., Fahrngruber H., Moore H.D., Schuurman H., Stütz A. (1997) A novel anti-inflammatory drug, SDZ ASM 981, for the topieal and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137:568–576

    Article  CAS  PubMed  Google Scholar 

  51. Meingassner J.G., Stütz A. (1992) Immunosuppressive macrolides of the type FK 506: a novel class of topieal agents for treatment of skin diseases? J Invest Dermatol 98: 851–855

    Article  CAS  PubMed  Google Scholar 

  52. Metzger W.J., Nyce J.W. (1999) Oligonucleotide therapy of allergie asthma. J Allergy Clin Immunol 104: 260–266

    Article  CAS  PubMed  Google Scholar 

  53. Milgrom H., Fiek R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., Metzger W.J. (1999) Treatment of allergie asthma with mono clon al anti-IgE antibody. N Engl J Med 341:1966–1973

    Article  CAS  PubMed  Google Scholar 

  54. Möller P., Czarnetzki B.M., Schadendorf D. (1995) Interleukin 7 in der Dermatologie. Molekulare, immunologische und präkinische Aspekte. Hautarzt 46: 676–682

    Article  PubMed  Google Scholar 

  55. Morel P., Revillard J.P., Nicolas J.F., Wijdenes J., Rizova H., Thivolet J. (1992) Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 5: 465–477

    Article  CAS  PubMed  Google Scholar 

  56. Mrowietz U. (1995) Safety considerations with cyclosporin and other systemie therapy in the treatment of severe psoriasis. Clin Drug Invest 10: 36–44

    Article  Google Scholar 

  57. Mrowietz U. (1999) Macrolide immunosuppressants. Eur J Dermatol 9: 346–351

    CAS  PubMed  Google Scholar 

  58. Mrowietz U. (1999) Treatment of psoriasis with fumarie acid esters. Dermatol Ther 11: 75–80

    Google Scholar 

  59. Mrowietz U., Christophers E., Altmeyer P. (1999) Treatment of severe psoriasis with fumarie acid esters: scientific background and guidelines for therapeutie use. The German fumarie acid ester consensus conference. Br J Dermatol 141: 424–429

    Article  CAS  PubMed  Google Scholar 

  60. Mrowietz U., Graeber M., Brautigam M., Thurston M., Wagenaar A., Weidinger G., Christophers E. (1998) The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topieally under occlusion. Br J Dermatol 139: 992–996

    Article  CAS  PubMed  Google Scholar 

  61. Mrowietz U., Zhu K., Christophers E. (2000) Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol 136: 675–676

    Article  CAS  PubMed  Google Scholar 

  62. Nashan D., Luger T.A. (2001) Zytokine, Stand und Perspektiven in der Behandlung von Hauttumoren. Hautarzt (im Druck)

    Google Scholar 

  63. Nasr I.S. (2000) Topical tacrolimus in dermatology. Clin Exp Dermatol 25: 250–254

    Article  CAS  PubMed  Google Scholar 

  64. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schaden dorf D. (1998) Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritie cells. Nat Med 4: 328–332

    Article  CAS  PubMed  Google Scholar 

  65. Nousari H.C., Sragovich A., Kimyai-Asadi A. (1999) Mycophenolate mofetil in autoimmune and inflammatory skin dis orders. J Am Acad Dermatol 40: 265–268

    Article  CAS  PubMed  Google Scholar 

  66. Ogata A., Nishimoto N., Yoshizaki K. (1999) Advances in interleukin-6 therapy. Rinsho Byori 47: 321–326

    CAS  PubMed  Google Scholar 

  67. Oh C.J., Das K.M., Gottlieb A.B. (2000) Treatment with antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinieal activity of psoriasis lesions. J Am Acad Dermatol 42: 829–830

    Article  CAS  PubMed  Google Scholar 

  68. Owen C.M., Harrison P.V. (2000) Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor mono clon al antibody. Clin Exp Dermatol 25: 195–197

    Article  CAS  PubMed  Google Scholar 

  69. Paul C., Graeber M., Stuetz A. (2000) Ascomycins: promising agents for the treatment of inflammatory skin diseases. Exp Opin Invest Drugs 9: 69–77

    Article  CAS  Google Scholar 

  70. Paul C., Ho V.C. (1998) Ascomycins in dermatology. Semin Cutan Med Surg 17: 256–259

    Article  CAS  PubMed  Google Scholar 

  71. Pisetsky D.S. (2000) Tumor necrosis factor blockers in rheumatoid arthritis. N Engl J Med 342: 810–811

    Article  CAS  PubMed  Google Scholar 

  72. Prinz J., Braun-Falco O., Meurer M., Daddona P., Reiter C., Rieber P., Riethmuller G. (1991) Chimaerie CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 338: 320–321

    Article  CAS  PubMed  Google Scholar 

  73. Rappersberger K., Komar M., Ebelin M.E., Scott G., Bueche M., Burtin P., Wolff K. (2000) Oral SDZ ASM981: safety, pharmacokineties and efficacy in patients with moderate to severe chronie plaque psoriasis. J Invest Dermatol 114: 776

    Google Scholar 

  74. Reitamo S., Rissanen J., Remitz A., Granlund H., Erkko P., Elg P., Autio P., Lauerma A.I. (1998) Tacrolimus ointment does not affect collagen synthesis: results of a singlecenter randomized trial. J Invest Dermatol 111: 396–398

    Article  CAS  PubMed  Google Scholar 

  75. Remitz A., Reitamo S., Erkko P., Granlund H., Lauerma A.I. (1999) Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 141: 103–107

    Article  CAS  PubMed  Google Scholar 

  76. Robinet E., Stamm C., Nicolas J.F., Faure M., Mercatello A., Coronel B., Wijdenes J., Bienvenue J., Revillard J.P., Claudy A. (1997) CD4 monoclonal antibody administration in atopie dermatitis. J Am Acad Dermatol 36: 582–588

    Article  CAS  PubMed  Google Scholar 

  77. Russell-Jones R. (2000) Interferon-alpha therapy for melanoma. Clin Exp Dermatol 25: 1–6

    Article  CAS  PubMed  Google Scholar 

  78. Ruzicka T., Bieber T., Schöpf E., Rubins A., Dobozy A., Bos J.D., Jablonska S., Ahmed I., Thestrup-Pedersen K., Daniel F., Finzi A., Reitamo S. (1997) A short-term trial oftacrolimus ointment for atopie dermatitis. European tacrolimus multicenter atopie dermatitis study group. N Engl J Med 337: 816–821

    Article  CAS  PubMed  Google Scholar 

  79. Rütter A., Luger T.A. (2001) High-dose intravenous immunoglobulins: a promising approach to treat severe immune-mediated and auto immune diseases ofthe skin. J Am Acad Dermatol (im Druck)

    Google Scholar 

  80. Saleh M.N., LeMaistre C.F., Kuzel T.M., Foss F., Platanias L., Schwartz G., Ratain M., Rook A., Freytes C.O., Craig F., Reuben J., Sams M.W., Niehols J.C. (1998) Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 39: 63–73

    Article  CAS  PubMed  Google Scholar 

  81. Schuler G., Kämpgen E. (1999) Vaccine therapy of malignant melanoma. Dermatol Ther 10: 62–73

    Google Scholar 

  82. Seder R.A., Gurunathan S. (1999) DNA vaccines-designer vaccines for the 21st century. N Engl J Med 341: 277–278

    Article  CAS  PubMed  Google Scholar 

  83. Shevach E.M. (1985) The effects of cyclosporin A on the immune system. Ann Rev Immunol 3: 397–423

    Article  CAS  Google Scholar 

  84. Slade H.B. (1998) Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. Eur J Dermatol 8: 13–16

    CAS  PubMed  Google Scholar 

  85. Smolen J.S., Kalden J.R., Scott D.L., Rozman B., Kvien T.K., Larsen A., Loew-Friedrieh I., Oed C., Rosenburg R. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multieentre trial. Lancet 353:259–266

    Article  CAS  PubMed  Google Scholar 

  86. Stadler R. (1998) Interferons in dermatology. Dermatol Ther 16: 377–398

    CAS  Google Scholar 

  87. Stadler R., Otte H-G., Luger T., Henz B.M., Kühl P., Zwingers T., Sterry W. (1998) Prospective randomized multicenter clinical trial on the use of interferon alpha-2a plus acitretin versus interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma stages 1 and 11. Blood 92: 3578–3581

    CAS  PubMed  Google Scholar 

  88. Stevens S.R., Hanifin J.M., Hamilton T., Tofte S.J., Cooper K.D. (1998) Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 134: 799–804

    Article  CAS  PubMed  Google Scholar 

  89. Surber C., Hin P., Buchner S. (1992) Clinical controversy on the effect of topical ciclosporin: what is the target site? Dermatol 185: 242–245

    Article  CAS  Google Scholar 

  90. Syed T.A., Ahmadpour O.A., Ahmad S.A., Ahmad S.H. (1997) Human leukocyte interferon-alpha in a hydrophilie cream versus in a gel for the treatment of genital herpes in males: a placebo-controlled, double-blind, comparative study. J Dermatol 24: 564–568

    Article  CAS  PubMed  Google Scholar 

  91. Tchah H., Lim B. (1999) Effect of FK 506 on the cornea: use of topical FK 506 in corneal transplantation in a guinea pig-rat model. Korean J Ophthalmol 13:71–77

    Article  CAS  PubMed  Google Scholar 

  92. Van Joost T., Heule F., Korstanje M., van den Broek M.J, Stenveld H.J., van Vloten W.A. (1994) Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 130: 634–640

    Article  PubMed  Google Scholar 

  93. Van Leent E.J., Graeber M., Thurston M., Wagenaar A., Spuls P.I., Bos J.D. (1998) Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 134: 805–809

    PubMed  Google Scholar 

  94. Zonneveld I.M., Rubins A., Jablonska S., Dobozy A., Ruzicka T., Kind P., Dubertret L., Bos J.D. (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134: 1101–1102

    CAS  Google Scholar 

Download references

Authors
  1. Thomas A. Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fortbildungswoche für Praktische Dermatologie und Venerologie e.V C/O Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität München, Frauenlobstraße 9-11, München, D-80337, Germany

    Gerd Plewig Prof. Dr. med.  & Klaus Degitz Priv.-Doz. Dr. med.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Luger, T.A. (2001). Neue immunmodulierende Strategien in der Dermatologie. In: Plewig, G., Degitz, K. (eds) Fortschritte der praktischen Dermatologie und Venerologie. Fortschritte der praktischen Dermatologie und Venerologie, vol 17. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56437-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56437-6_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-66650-9

  • Online ISBN: 978-3-642-56437-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation